Angiosarcoma of the scalp successfully treated with pazopanib Hajime Tomita, MD, PhD, Yuta Koike, MD, PhD, Misachi Asai, MD, Fumihide Ogawa, MD, PhD, Kuniko Abe, MD, PhD, Miki Tanioka, MD, PhD, Atsushi Utani, MD, PhD Journal of the American Academy of Dermatology Volume 70, Issue 1, Pages e19-e21 (January 2014) DOI: 10.1016/j.jaad.2013.08.055 Copyright © 2013 American Academy of Dermatology, Inc. Terms and Conditions
Fig 1 Angiosarcoma treated with pazopanib. Improvements in edema and erythema and a reduction in the size of the left cheek indurated plaque are seen following pazopanib therapy. A, Before pazopanib therapy. B, Fourteen days after the commencement of pazopanib therapy. Journal of the American Academy of Dermatology 2014 70, e19-e21DOI: (10.1016/j.jaad.2013.08.055) Copyright © 2013 American Academy of Dermatology, Inc. Terms and Conditions
Fig 2 Angiosarcoma treated with pazopanib. Serial computed tomography scans. Scans show varying responses in multiple intraparotid lymph nodes (arrows). A, Before pazopanib therapy. B, Nineteen days after the commencement of pazopanib therapy. Journal of the American Academy of Dermatology 2014 70, e19-e21DOI: (10.1016/j.jaad.2013.08.055) Copyright © 2013 American Academy of Dermatology, Inc. Terms and Conditions